Aerovate Therapeutics, Inc. (AVTE)

NASDAQ: AVTE · Real-Time Price · USD
2.790
+0.340 (13.88%)
At close: Nov 1, 2024, 4:00 PM
2.731
-0.059 (-2.11%)
After-hours: Nov 1, 2024, 7:02 PM EDT
13.88%
Market Cap 80.54M
Revenue (ttm) n/a
Net Income (ttm) -87.94M
Shares Out 28.87M
EPS (ttm) -3.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,787,888
Open 2.490
Previous Close 2.450
Day's Range 2.490 - 2.800
52-Week Range 1.250 - 32.420
Beta 1.03
Analysts Hold
Price Target 11.75 (+321.15%)
Earnings Date Nov 11, 2024

About AVTE

Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial. The company was incorporated in 2018 and is headquartered in Waltham, Massachusetts. [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2021
Employees 51
Stock Exchange NASDAQ
Ticker Symbol AVTE
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AVTE stock is "Hold." The 12-month stock price forecast is $11.75, which is an increase of 321.15% from the latest price.

Price Target
$11.75
(321.15% upside)
Analyst Consensus: Hold
Stock Forecasts

News

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders

NEW YORK , Nov. 1, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches ...

Other symbols: PFIE
21 hours ago - PRNewsWire

Aerovate Therapeutics to Explore Strategic Alternatives

WALTHAM, Mass., July 08, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), which previously announced it was halting enrollment and shutting down the Phase 3 portion of the Inhaled ...

4 months ago - GlobeNewsWire

Investigation Into Aerovate Therapeutics, Inc. (AVTE) Announced byHolzer & Holzer, LLC

ATLANTA, June 21, 2024 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Aerovate Therapeutics, Inc. (“Aerovate” or the “Company”) (NASDAQ: AVTE) complied with federal securities laws....

4 months ago - GlobeNewsWire

Aerovate Therapeutics Investors: Investigation on behalf of investors; the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their losses

4 months ago - GlobeNewsWire

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses AV-101 did not meet the primary endpoint of change in pulmonary vascular resistan...

4 months ago - GlobeNewsWire

Aerovate: Imatinib Delivery Change Leads To Targeting Of Massive PAH Market

Aerovate Therapeutics, Inc. results from the phase 2 portion of the phase 3 IMPAHCT trial, using AV-101 for the treatment of patients with pulmonary arterial hypertension, expected in June 2024. The g...

5 months ago - Seeking Alpha

Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference

Baseline characteristics reflect a PAH population with significant disease Topline data from Phase 2b portion of IMPAHCT study to be released in June 2024 Enrollment into the Phase 3 portion of IMPAHC...

5 months ago - GlobeNewsWire

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

WALTHAM, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives ...

6 months ago - GlobeNewsWire

Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference

WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients...

7 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights

WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...

7 months ago - GlobeNewsWire

Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair

WALTHAM, Mass., March 06, 2024 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that improve the lives of patients...

8 months ago - GlobeNewsWire

Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

Topline Phase 2b data expected in June 2024 More than 120 sites around the world actively recruiting in the Phase 3 portion of the IMPAHCT trial WALTHAM, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Aerov...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights

WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights

WALTHAM, Mass., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors

WALTHAM, Mass., July 11, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

1 year ago - GlobeNewsWire

Aerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAH

Aerovate: Smart Investment Opportunity With This Developer Of Inhaled Imatinib For PAH

1 year ago - Seeking Alpha

Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference

WALTHAM, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference

Direct delivery of imatinib to the lungs in nonclinical species demonstrated increased lung exposure compared with oral or IV dosing

1 year ago - GlobeNewsWire

Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights

WALTHAM, Mass., May 15, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives ...

1 year ago - GlobeNewsWire

Aerovate: Small Mid-Stage Biotech Targeting Multibillion-Dollar PAH Market

AVTE reported Q4 2023 earnings in line with expectations and has enough cash runway until H2 2025. AV-101, AVTE's lead asset, is on track with patient enrollment in phase 2b PAH trial, and top-line Ph...

1 year ago - Seeking Alpha

Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights

WALTHAM, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...

1 year ago - GlobeNewsWire

Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference

WALTHAM, Mass., March 02, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the live...

1 year ago - GlobeNewsWire

Aerovate: Developing An Exciting PAH Drug, Initiating With A Buy

Aerovate is a SMID-cap biotech developing an inhaled imatinib for pulmonary arterial hypertension. AV-101's Phase 2b PAH data is expected in 4Q 2023 or 1Q 2024, which we believe will be positive.

1 year ago - Seeking Alpha

Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors

WALTHAM, Mass., Jan. 23, 2023 (GLOBE NEWSWIRE) -- Aerovate Therapeutics, Inc. (Nasdaq: AVTE), a clinical-stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives...

1 year ago - GlobeNewsWire

Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research

Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants Phase 1 results showed that AV-101 ...

2 years ago - GlobeNewsWire